While it remains uncertain which strategy will prove most effective, tailored approaches - incorporating immunotherapy and other combinations based on cancer type, tissue origin, KRAS mutations, and downstream effectors – are likely required to achieve durable responses. This evidence concerns the gene KRAS and cancer.